The ALECSAT therapy supplements and strengthens the patient’s own immune system to prepare the fight against cancer cells in the same way as the body’s own defense in healthy people. Since Cytovac only applies the patient’s own cells, this treatment is gentle and with only very few side effects compared to several standard of care procedures.
The ALECSAT therapy attacks the cancer cells in several ways as the reinjected cells recognize more than one property of the cancer cells. Hence, should the cancer cells change or should there be several different cancer cell types, all of them could be subject to attack and destruction by the reinjected cells used in the ALECSAT therapy.
Cancer cells exert inhibition on the immune system cells in-vivo, but as the ALECSAT cells are manufactured ex-vivo in cell culture laboratories – no inhibiting effect of the cancer cells can take place. Thus, ALECSAT products can also be manufactured for patients with immune systems that have been suppressed by the cancer.
The ALECSAT therapy will provide the patient with millions of active cells that can attack the cancer cells in the body; this may stop tumor growth and reduce the tumor size. In addition, the most recent results from clinical trials performed by Cytovac indicate that the ALECSAT therapy may reactivate existing, but suppressed, immune system cells in the patient’s body. Hence, these cells may also become active against the cancer cells.
Together these multiple mechanisms may give the immune system the possibility to win the battle against the cancer cells potentially stopping or curing the cancer disease.
Moreover, the ALECSAT therapy may also protect the patient against disease relapse. The reason being that the product used in the ALECSAT therapy also contains ‘memory cells’ that may persist in the body thus being prepared should new cancer cells develop. These ´memory cells´ may effectively support the defense against new cancer cells.